Change search
ReferencesLink to record
Permanent link

Direct link
Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
Department of Endocrinology Erasmus Medical Center, Rotterdam, Netherlands et al .
1Department of Endocrinology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
Department of Endocrinology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
Show others and affiliations
2015 (English)In: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 173, no 3Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To evaluate extended dosing intervals (EDIs) with lanreotide Autogel 120 mg in patients with acromegaly previously biochemically controlled with octreotide LAR 10 or 20 mg.

DESIGN AND METHODS: Patients with acromegaly had received octreotide LAR 10 or 20 mg/4 weeks for ≥ 6 months and had normal IGF1 levels. Lanreotide Autogel 120 mg was administered every 6 weeks for 24 weeks (phase 1); depending on week-24 IGF1 levels, treatment was then administered every 4, 6 or 8 weeks for a further 24 weeks (phase 2). Hormone levels, patient-reported outcomes and adverse events were assessed.

PRIMARY ENDPOINT: proportion of patients on 6- or 8-week EDIs with normal IGF1 levels at week 48 (study end).

RESULTS: 107/124 patients completed the study (15 withdrew from phase 1 and two from phase 2). Of 124 patients enrolled, 77.4% were allocated to 6- or 8-week EDIs in phase 2 and 75.8% (95% CI: 68.3-83.3) had normal IGF1 levels at week 48 with the EDI (primary analysis). A total of 88.7% (83.1-94.3) had normal IGF1 levels after 24 weeks with 6-weekly dosing. GH levels were ≤ 2.5 μg/l in > 90% of patients after 24 and 48 weeks. Patient preferences for lanreotide Autogel 120 mg every 4, 6 or 8 weeks over octreotide LAR every 4 weeks were high.

CONCLUSIONS: Patients with acromegaly achieving biochemical control with octreotide LAR 10 or 20 mg/4 weeks are possible candidates for lanreotide Autogel 120 mg EDIs. EDIs are effective and well received among such patients.

Place, publisher, year, edition, pages
2015. Vol. 173, no 3
National Category
Endocrinology and Diabetes
URN: urn:nbn:se:liu:diva-125233DOI: 10.1530/EJE-15-0215PubMedID: 26047625OAI: diva2:903706

Bertil Ekman, vid avdelningen för kardiovaskulär medicin samt endokrinmedicinska kliniken, tillhör "LEAD Study Group".

Available from: 2016-02-16 Created: 2016-02-16 Last updated: 2016-04-27

Open Access in DiVA

fulltext(394 kB)30 downloads
File information
File name FULLTEXT01.pdfFile size 394 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed
In the same journal
European Journal of Endocrinology
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 30 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 274 hits
ReferencesLink to record
Permanent link

Direct link